Detection of rifampicin and izoniazid resistance in Mycobacterium tuberculosis strains from Samara Region (Central Russia) by Drobniewski, F. et al.

the isolated VGS was performed with the E-test method (AB Biodisk, Solna,
Sweden) on Mueller-Hintons medium. Isolates of VGS resistant to penicillin
(MIC> 2.0mg/L) were also tested for susceptibilities to linezolid, erythro-
mycin, vancomycin and ciproﬂoxacin. Clinical data as fever and mucositis on
admission were registered. Chemotherapy, ongoing antibiotic treatment,
antibiotic prophylaxis, as well as previous antibiotic treatment up to 1 year
before start of the study were registered.
Results:One patient was excluded because of a Staphylococcus aureus infection
in the stem cell harvest. In 48/49 patients VGS was isolated from the oral
cavity. Twelve of 48 (25%) patients had VGS strains that were resistant to
penicillin (MIC> 2.0mg/L). Eleven of the isolates were identiﬁed as Strep-
tococcus mitis and one as Streptococcus sanguis. The patients that harboured
penicillin resistant VGS (MIC> 2.0mg/L) had more septicemias (P¼ 0.04)
and more days of treatment with trimethoprim-sulphametoxazole than
patients with susceptible or intermediately resistant VGS (P¼ 0.04). There
were no other statistical signiﬁcant differences between the two groups. Four
of 12 isolates resistant to penicillin were also resistant to erythromycin
(MIC> 0.5mg/L).
Conclusions:We summarize that 25% of the patients had oral VGS resistant to
penicillin that is higher than expected. This group of patients gets higher
burden of antibiotic therapy due to infections after chemotherapy that might
select penicillin resistant VGS strains.
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Objective: To estimate difference regarding epidemiology, outcome and
resistance (R) to antimicrobials of medical patients with bacteremia (B), over
a 6-year period, i.e. 1997–2002.
Methods: Prospective demographic, clinical and microbiology, as well as
hospital stay and outcome, data entry of medical patients with documented B.
Time January 1997 to December 2002. Data entry and analysis in IBM
compatible PC using EPI5-Info (CDC, 1993) programme. Sensitivity as by
Kirby-Bauer, statistics by Yates corrected/2.
Results:Documented B in a total of 301 pts (M: 47.2%, F: 52.8%) mean age
69.6 years. Chronic disease present in 79.5%, and nosocomial Aˆ in 24.5% of
patients. More frequent pathogens were E. coli (37%) S. aureus (15.6%), and
most common source of B was the urinary tract (42%). Main difference
between ﬁrst and second half of the studied period was the rise of Klebsiella sp.
from 2.1 to 12.6% and relative rise of Enterococcal B and Candidemias.
Regarding R data of Gram-pathogens, signiﬁcance was most prominent to
3rd generation cephalosporins [rising from 6.9 to 20.4%, P¼ 0.024] and
ciproﬂoxacin [9.0–19.4%, P¼ 0.06]. The annual rise of Gram þ cocci
percentage is noted, without, fortunately, a rise to either MRSA rates or
glycopeptide R. Mean hospital stay was 13.4 days and mortality during stay
was 18%, though not always directly attributed to B.
Conclusions: The constant variability of B pathogens, the appearance of less
expected ones, and mainly R proﬁle changes deem continuous surveillance
and awareness, to ensure the optimal empirical antimicrobial choice based on
the most recent data of the given milieux.
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Introduction: Recently high rates of tuberculosis incidence and prevalence
are observed in civilian and prisons sectors in Russia. One of the main reasons
for high morbidity levels and ineffectiveness of treatment is wide spreading of
drug resistant Mycobacterium tuberculosis strains, but accurate and comprehen-
sive information on levels of drug resistance among strains circulating in
Central Russia is unavailable.
Objective:Rifampicin and izoniazid resistance detection in TB isolates from
Samara (Central Russia) civilian and prison TB hospitals and dispensaries in
2000–2002 by revealing mutations in rpoB, katG and inhA genes using
Macroarray technique.
Methods: A total of 342 M. tuberculosis isolates were tested using Macroarray
method. It is based on multiplex ampliﬁcation of rpoB, katG and inhA genes
fragments (with three pairs of biotin labeled primers) following by dot-
hybridization with normal and mutant oligonucleotide probes (fragments of
rpoB, katG and inhA genes in which mutations occur) immobilized on nylon
membrane strips. Mycobacterial DNA was extracted by heating of cell
suspensions following by chloroform extraction. Streptavidin-alkaline phos-
phatase color development system was used for visualization of results.
Results and conclusions: In total, 78.8% of isolates was determined to be
resistant to one or more drugs. From those, 66.3%were resistant to rifampicin
and 92.9% to izoniazid. Izoniazid resistance in themost part of isolates (88.4%)
was due to the mutation in 315 codon of katG gene. The percentage of
resistant mycobacteria was higher in those isolated from prisoners than from
civilians (84.7 and 75.1%, respectively). From resistant isolates 165 specimens
(48.2%) possessed mutations both in rpoB and katG (or inhA) genes and were
determined as multidrug resistant (MDR). It proves the fact that rifampicin
resistance is very often combined with izoniazid resistance and serves as
indicator of MDR. Very high prevalence of MDR M. tuberculosis strains in
Central Russia reﬂects general TB situation in Russian Federation and other
countries of the former Soviet Union and is a serious problem for doctors and
public health in general.
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Introduction: Linezolid, an oxazolidinone antibiotic, has a unique mode of
action and is effective against a broad range of resistant and sensitive gram
positive infections. In order to prevent misuse of this useful agent the
antibiotic committee for Tayside hospitals decided on a number of strategies
to control prescribing. These included agreement on appropriate clinical
situations for use of linezolid (below), all prescriptions are subject to approval
by infection specialists and continual monitoring by clinical pharmacists.
Objectives: Review the clinical experience of linezolid use and compliance
with our guidelines.
Method:Clinical pharmacists recorded information on all patients prescribed
linezolid and ensured approval had been obtained from an infection specialist.
Medical notes were reviewed retrospectively for patients prescribed linezolid
since its introduction (19months). Data were collected on organisms, pre-
vious therapy, indications, duration of therapy, clinical and microbiological
outcomes and linezolid related adverse reactions.
Results: Forty courses of linezolid were prescribed, notes were reviewed for
33 of these patients. A number of patients ﬁtted more than one criteria for use
of linezolid (n¼ 45). See table.
There was 100% compliance with our guidelines. Seventy-six percent of
prescriptions for linezolid were for indications not currently licensed in the
UK. The majority of patients (27) were treated for MRSA/MRSE infections.
Eleven patients had a bone or joint infection. Thirty patients had previously
been treated with a glycopeptide. The mean duration of therapy was 23 days.
28/33 patients had clinical outcome documented and 26 (92%) were classiﬁed
as cure or improved. 8/33 patients had a linezolid related adverse reaction, all
were fully reversible.
Conclusions: Compliance with our guidelines was excellent and our control
measures for prescribing have proved effective. Linezolid was used in awide of
range of clinical scenarios with good outcomes. This study represents the ﬁrst
Clinical situation %
VRE 9
Hypersensitivity or intolerance to previous regimen 24
Clinical failure or lack of improvement 11
Poor IV access 7
Patient no longer wishing IV therapy 24
Deteriorating renal function 9
Drug interaction with rifampicin or concern about hepatotoxicity 7
Facilitation of hospital discharge by switching to oral therapy 9
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